Report

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Science  04 Jun 2004:
Vol. 304, Issue 5676, pp. 1497-1500
DOI: 10.1126/science.1099314

You are currently viewing the abstract.

View Full Text

Abstract

Receptor tyrosine kinase genes were sequenced in non–small cell lung cancer (NSCLC) and matched normal tissue. Somatic mutations of the epidermal growth factor receptor gene EGFR were found in 15of 58 unselected tumors from Japan and 1 of 61 from the United States. Treatment with the EGFR kinase inhibitor gefitinib (Iressa) causes tumor regression in some patients with NSCLC, more frequently in Japan. EGFR mutations were found in additional lung cancer samples from U.S. patients who responded to gefitinib therapy and in a lung adenocarcinoma cell line that was hypersensitive to growth inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell lines. These results suggest that EGFR mutations may predict sensitivity to gefitinib.

    View Full Text

    Cited By...